UnknownNCT03636763
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
Studying Bullous pemphigoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Principal Investigator
- EMILIE GARRIDO PRADALIEAPHM
- Intervention
- data report(drug)
- Enrollment
- 183 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2019
Study locations (1)
- Assistance Publique Des Hopitaux de Marseille, Marseille, PACA, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03636763 on ClinicalTrials.govOther trials for Bullous pemphigoid
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06291350Peridontal and Intestinal Microbiota in Patients With Gingival Scarring PemphigoidCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06479018Deciphering IL-17-dependant Inflammatory Response in Bullous PemphigoidCHU de Reims
- RECRUITINGNCT04198740Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular SurfaceCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT03295383Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidUniversity Hospital, Rouen